



an Open Access Journal by MDPI

New Insights in Aneurysmal Subarachnoid Hemorrhage Pathogenesis and Its Impact on Outcome and Treatment

Guest Editors:

Dr. Michel Roethlisberger

Department of Neurosurgery,
Universitätsspital Basel, Basel,
Switzerland

Dr. Basil Grüter

1. Institute of Neuroradiology,
Aarau Cantonal Hospital, 5001
Aarau, Switzerland
2. Department of Neuroradiology,
Timone Hospital, Marseille,
France

Dr. Isabel Hostettler

Department of Neurosurgery,
Kantonsspital St. Gallen,
University of St. Gallen, St. Gallen,
Switzerland

Deadline for manuscript
submissions:

closed (30 November 2023)

Message from the Guest Editors

Aneurysmal subarachnoid hemorrhage is a complex disease following intracranial aneurysm rupture and leading to a protracted clinical course due to the circulating blood products in the cerebrospinal fluid. Although many factors influencing the overall outcome are known, the specific impact of a specific aneurysm morphology, anatomic location and/or size, as well as patient sex are less frequently addressed as factors influencing the overall patient outcome. We aim to explore how the neuro-anatomical factors of a ruptured intracranial aneurysm influence treatment decisions, clinical course and outcome of patients with aneurysmal subarachnoid hemorrhage.

Research areas may include:

- preclinical/clinical studies on aneurysm morphology in aneurysmal subarachnoid hemorrhage models, especially within the context of pathogenesis mechanisms and translational research;
- clinical cohort studies addressing risk-factor and predictive models with an emphasis on aneurysm morphology, location, size and patient-specific factors (e.g., sex or age);
- and preclinical/clinical studies where neuro-anatomical and morphological factors are used for specific open-vascular or endo-vascular treatment.



mdpi.com/si/156881



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI